A5022308366- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- Liver Disease and Transplantation
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Esophageal and GI Pathology
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Abdominal vascular conditions and treatments
- Liver Disease Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Organ Transplantation Techniques and Outcomes
- Gallbladder and Bile Duct Disorders
- Pleural and Pulmonary Diseases
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Cancer Treatment and Pharmacology
- Tracheal and airway disorders
- Medical Imaging and Pathology Studies
- Renal cell carcinoma treatment
- MRI in cancer diagnosis
- Cancer Genomics and Diagnostics
- Cancer Mechanisms and Therapy
- Gastrointestinal disorders and treatments
- Medical Imaging Techniques and Applications
- Salivary Gland Tumors Diagnosis and Treatment
Aichi Cancer Center
2016-2025
Nippon Medical School
2019-2025
Japanese Foundation For Cancer Research
2022-2024
Kanagawa Cardiovascular and Respiratory Center
2020-2022
Chiba Hokusou Hospital
2018-2019
Ebina General Hospital
2019
Aichi Medical University
2015
Society of Interventional Radiology
2010-2011
Nara Medical University
2010
Iwate Medical University
2009
Background Although radiofrequency ablation (RFA) is widely performed for the treatment of colorectal cancer (CRC) lung metastases, its efficacy candidates with surgically resectable disease unclear. Purpose To evaluate prognosis after RFA in participants CRC metastases. Materials and Methods For this prospective multicenter study (ClinicalTrials.gov identifier: NCT00776399), five or fewer metastases measuring 3 cm less were included. Participants a total 100 0.4-2.8 (mean, 1.0 ± 0.5) chosen...
Background. Two standard sets of criteria are used to evaluate the tumor response hepatocellular carcinoma (HCC): RECIST (Response Evaluation Criteria in Solid Tumors) and modified (mRECIST). The purpose was compare two evaluation criteria, version 1.1 mRECIST, for HCC treated using transcatheter arterial chemoembolization (TACE). Methods. radiological findings patients who underwent TACE HCCs a multicenter clinical trial were examined. Sixty-five lesions 21 with without mixing iodized-oil...
Hepatocellular carcinoma is one of the leading causes cancer-related death both in Japan and globally. In advanced stage, hepatic arterial infusion chemotherapy (HAIC) most commonly used treatment options for liver cancer Japan, implantation a catheter system (called port system) body method that has evolved mainly Japan. The Guideline Committee Japanese Society Interventional Radiology Implantable Port Assisted Treatment jointly published clinical practice guidelines HAIC with to ensure its...
Managing malignant pleural effusion (MPE) with pleurodesis is essential for symptom relief and minimizing the need repeated thoracentesis. Interstitial lung disease (ILD) one of most common complications associated advanced cancer. However, efficacy safety MPE secondary to cancer ILD remains unclear. This study aimed evaluate in this population. was a single-center retrospective analysis. The cases patients complicated at Nippon Medical School Hospital (Tokyo, Japan) between January 2010...
Abstract Background Atezolizumab plus bevacizumab is recommended as a first-line treatment for unresectable hepatocellular carcinoma (uHCC). A subgroup analysis of the IMbrave150 trial showed shorter overall survival (OS) in uHCC patients with stable disease (SD) than complete response (CR) or partial (PR) after atezolizumab bevacizumab. Improving OS SD an unmet medical need. Transcatheter arterial chemoembolization (TACE) may enhance efficacy by controlling intrahepatic lesions and...
Objective:The purpose of this study was to investigate retrospectively the clinical procedural performance CT-guided needle biopsy for retroperitoneal lesions.Materials and Methods: performed in 74 consecutive patients (M:F = 44:30; mean age, 59.7 years) with lesions between April 1998 June 2009.The target lesion ranged from 1.5 12.5 cm size.The access path 3.5 11.5 depth.A specimen obtained using an 18-gauge core under a CT or CT-fluoroscopy guidance patient local anesthesia.The...
No established therapy exists for unresectable intrahepatic cholangiocarcinoma (ICC). We conducted a phase I/II study to ascertain the recommended dose (RD) of hepatic arterial infusion using gemcitabine (GEM) ICC and assess efficacy safety.For patients with ICC, GEM was administered through artery via port system as 30-minute on days 1, 8, 15 every 4 weeks 5 cycles. In I, dosage levels 2, 3 set at 600, 800, 1000 mg/m, respectively, increased in 6 time. Maximum tolerated defined resulting...
Coronavirus disease 2019 (COVID-19) has been recognized as a worldwide pandemic. However, the clinical course of COVID-19 remains poorly characterized. Although some cases pneumothorax have reported, they all had pulmonary complications or were managed with mechanical ventilation. We herein report case that developed even though patient no underlying diseases and never In present case, lung bulla was found on chest computed tomography during treatment for COVID-19. concluded affected...